Shopping Cart
Remove All
Your shopping cart is currently empty
RSV604 ((S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea) is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $34 | In Stock | In Stock | |
| 5 mg | $55 | In Stock | In Stock | |
| 10 mg | $97 | In Stock | In Stock | |
| 25 mg | $198 | In Stock | In Stock | |
| 50 mg | $372 | In Stock | In Stock | |
| 100 mg | $596 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $61 | In Stock | In Stock |
| Description | RSV604 ((S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea) is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM) |
| Targets&IC50 | Nucleocapsid protein:1.6 μM (Kd) |
| In vitro | RSV-604 increases viability of RSV-infected HEp-2 cells (EC50 = 0.86 μM) and inhibits RSV replication in human airway epithelial (HAE) cell monolayers following mucosal inoculation[1]. |
| In vivo | RSV604 resistance mutations in the N protein. RSV604 engaged in two different MoAs in HeLa cells, inhibiting both RSV RNA synthesis and the infectivity of released virus. RSV604 did not inhibit viral RNA synthesis in the RSV subgenomic replicon cells or in the cell-free RNP assay, suggesting that it might act prior to viral replication complex formation. RSV604 did not alter N protein localization in the infected cells[2]. |
| Synonyms | (S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea |
| Molecular Weight | 388.39 |
| Formula | C22H17FN4O2 |
| Cas No. | 676128-63-5 |
| Smiles | Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 195 mg/mL (502.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.